HCC in disease context refers to hepatocellular carcinoma, the most common primary liver cancer in adults. It frequently arises in the setting of chronic liver disease and cirrhosis, especially with hepatitis B or C and metabolic/alcohol-related liver injury. Prognosis is strongly stage-dependent and often poor in advanced disease.
Tempest Therapeutics reported 2025 financial results showing $7.7 million in cash and highlighted clinical progress including 100% complete response rate in TPST-2003 CAR-T trial and multiple FDA designations for amezalpat in hepatocellular carcinoma. The company completed strategic CAR-T asset acquisition and plans Phase 2b registrational study for its lead program in 2026.
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
Nivolumab plus ipilimumab demonstrates survival benefits in unresectable hepatocellular carcinoma but exceeds US cost-effectiveness thresholds at current pricing, with extended dosing intervals or price reductions needed for economic viability.
CAR T-cell therapy market advances with AI-driven manufacturing improvements and over 250 companies developing 500+ drug candidates, including breakthrough solid tumor treatments and GPC3-targeted therapies for hepatocellular carcinoma.
The FDA has granted Fast Track designation to PLT012, a first-in-class anti-CD36 monoclonal antibody for hepatocellular carcinoma treatment. The Phase 1 trial is currently enrolling patients in Texas.
Researchers at RIKEN Center for Integrative Medical Sciences in Japan have developed a machine-learning algorithm that predicts hepatocellular carcinoma risk by analyzing the MYCN protein and tumor-promoting microenvironments in liver tissue before malignancy manifests.
CStone Pharmaceuticals received FDA IND clearance to initiate a Phase II trial of CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors across nine cancer indications.
CStone Pharmaceuticals received FDA IND clearance to begin a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGF, and CTLA-4, in advanced solid tumors across nine cancer indications.
Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07589244 |
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC |
RECRUITING | PHASE2/PHASE3 |
| NCT07379489 |
Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma |
NOT_YET_RECRUITING | |
| NCT07353333 |
Preliminary Evaluation of Clinical Application of SPECT Imaging Targeting GPC3 |
NOT_YET_RECRUITING | NA |
| NCT07352007 |
Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular |
NOT_YET_RECRUITING | PHASE2 |
| NCT07350824 |
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC |
NOT_YET_RECRUITING | NA |
| NCT07350070 |
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension |
NOT_YET_RECRUITING | PHASE2 |
| NCT07340502 |
TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma |
NOT_YET_RECRUITING | |
| NCT07334483 |
A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC |
RECRUITING | PHASE2 |
| NCT07300488 |
Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma |
ACTIVE_NOT_RECRUITING | PHASE2/PHASE3 |
| NCT07272200 |
Understanding Gene ENvironment Interaction in ALcohol-related Hepatocellular Carcinoma |
RECRUITING | NA |
